Stockreport
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't [Seeking Alpha]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Despite a recent $11bn M&A spree targeting oncology and immunology, GILD faces skepticism due to a poor track record and lack of near-term revenue from new acquisitions. I expect Q1 earnings to be somewhat underwhelming, with sluggish growth and minor IPR&D charges, but GILD trades at a below-average forward P/E of ~16x versus peers. I continue to hold GILD for its robust HIV franchise and 2% dividend yield while awaiting evidence that management can successfully execute on oncology ambitions. Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » Michael Vi/iStock Editorial via Getty Images Investment Overview - Background To Q1 Earnings & M&A Spree Gilead Sciences, Inc. ( GILD ), the Foster City, California-based Pharma giant, is set to announce its Q1 earnings on 23rd April - this Thursday. Analysts' consensus revenue More on my IG service If you are interested in keeping up to date with stocks making moves wit
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Arcus halts Gilead-partnered late-stage trial for lung cancer drug [Seeking Alpha][Seeking Alpha]
- Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance][Yahoo! Finance]
- Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer[Business Wire]
- More
GILD
SEC Filings
SEC Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website
- More